Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.55) per share which missed the analy

HUNTSVILLE, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company")

HUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Comp

- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the en

- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the en

HUNTSVILLE, Ala. , July 22, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Com

Seres Therapeutics NASDAQ: MCRB reported results from an investigator-sponsored study of SER-155 in

Data Safety Monitoring Committee completed initial review of sentinel dosing observations and recomm

80% of SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary s

BTIG analyst Thomas Shrader initiates coverage on Serina Therapeutics (AMEX:SER) with a Buy ratin

Gannet BioChem, a leading life sciences manufacturing company, today announced a development partner

HUNTSVILLE, Ala., June 30, 2026 (GLOBE NEWSWIRE) -- Gannet BioChem , a leading life sciences manufac

CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leadi

https://www.sec.gov/Archives/edgar/data/1708599/000149315226025007/forms-3.htm

SER-252 Phase 1b Registrational Clinical Study: Following dosing of the first patient in February 20

Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.58) per share which missed the analy

Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson's Disease; TFL data

Data highlight both SER-603's rational design that targets microbial functions linked to mucosal hea

Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrie

Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrie

– Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity

HUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company")

Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.31) per share which beat the analyst

- FDA Grants IND Clearance for SER-252- SER-252 Phase 1b Trial Initiated- Closed Private Placement F

HUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE Americ

(Editor’s note: The future prices of benchmark tracking ETFs, and the headline were updated in the s

U.S. stock futures declined on Friday following Thursday's declines. Futures of the major benchmark

US stocks down, Dow falls 300+ points, S&P 500 drops 0.93%, Nasdaq falls 1.25%. Energy shares up

Five Below Inc (FIVE) shares rose 7.2% in pre-market trading after reporting better-than-expected Q4

Serina Therapeutics Inc. surged 39.45% in after-hours trading Wednesday following a $15 million priv

- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 mill

- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort

META: 10% | Meta Platforms shares are trading higher after the company reported better-than-expected

Serina Therapeutics shares jumped nearly 35% after the FDA cleared its IND application for SER-252,